Last reviewed · How we verify
Methotrexate - Immediate
Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.
Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division. Used for Acute lymphoblastic leukemia (ALL), Osteosarcoma, Breast cancer.
At a glance
| Generic name | Methotrexate - Immediate |
|---|---|
| Also known as | conventional methotrexate treatment |
| Sponsor | University Hospital, Montpellier |
| Drug class | Antimetabolite; folate antagonist |
| Target | Dihydrofolate reductase (DHFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Immunology; Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Methotrexate is a folate antagonist that binds to dihydrofolate reductase and prevents the conversion of dihydrofolate to tetrahydrofolate, a critical cofactor in one-carbon transfer reactions. This disrupts nucleotide synthesis, leading to inhibition of rapidly dividing cells including cancer cells and activated immune cells. The drug is used both as a cytotoxic chemotherapy agent and as an immunosuppressant at lower doses.
Approved indications
- Acute lymphoblastic leukemia (ALL)
- Osteosarcoma
- Breast cancer
- Rheumatoid arthritis
- Psoriasis
- Inflammatory bowel disease
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Mucositis
- Nausea and vomiting
- Hepatotoxicity
- Nephrotoxicity
- Neurotoxicity (CNS effects)
- Alopecia
- Infection
Key clinical trials
- Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule (NA)
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (PHASE2)
- MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial (PHASE2)
- Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease (PHASE3)
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (PHASE2, PHASE3)
- Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy (NA)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methotrexate - Immediate CI brief — competitive landscape report
- Methotrexate - Immediate updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI